牛至油体外抗肿瘤活性研究

目的观察牛至油对肿瘤细胞株的生长抑制作用。方法采用MTT法检测不同浓度的牛至油对体外培养的多种肿瘤细胞株的生长抑制作用,计算半数抑制浓度(IC50)。结果不同浓度牛至油作用后,人肝癌细胞系HepG2、人子宫颈癌细胞系JTC-26和肺癌细胞系A549出现增殖阻滞。MTT法确定牛至油对肝癌HepG2的IC50为118μg/ml;人子宫颈癌JTC-26的IC50为118μg/ml;肺癌A549的IC50为59μg/ml。结论牛至油具有体外抗肿瘤活性。     

夜香树提取物体外抗肿瘤作用的实验研究

为探讨夜香树(CN)不同提取物体对体外培养的肿瘤细胞的作用,采用系统溶剂法提取CN皂苷和多糖,采用MTT法、细胞集落形成法、生长曲线法观察CN皂苷和多糖对宫颈癌细胞株Hela、人胃癌细胞株SGC7901、人肝癌细胞株Bele7404的生长抑制情况,结果发现CN皂苷和多糖对人胃癌细胞株SGC7901、宫颈癌细胞株Hela、肝癌细胞株Bele7404、等3种肿瘤细胞均有明显的抑制作用:在终浓度为62.5 μg/mL范围,CN皂苷和多糖对上述3种肿瘤细胞的抑制率均大于80%,细胞抑制率均有明显的剂量依赖性,IC50均小于20 μg/mL.CN皂苷和多糖对宫顶癌细胞株Hela、人胃癌细胞株SGC7901、人肝癌细胞株Bele7404细胞有显著的抗增殖作用,其抗增殖作用呈明显的剂量依赖关系.     

ODC, AdoMetDC双反义腺病毒对肺癌增殖和侵袭抑制作用的体外和体内研究

鸟氨酸脱羧酶(ODC)和S-甲硫氨酸脱羧酶(AdoMetDC)是多胺体内合成的2个关键酶.研究腺病毒Ad-ODC-AdoMetDCas介导的ODC和AdoMetDC反义RNA对肺癌多胺合成,细胞增殖以及侵袭的抑制作用.用活细胞计数和流式细胞术分别检测Ad-ODCas和Ad-ODC-AdoMetDCas对肺癌A-549细胞增殖的影响,蛋白质印迹和HPLC方法分别检测腺病毒对肺癌A-549细胞中ODC和AdoMetDC蛋白表达以及胞内多胺含量的抑制作用,TUNEL标记检测法观察Ad-ODC-AdoMetDCas对肺癌细胞凋亡的影响,Matrigel侵袭实验分析腺病毒对肺癌A-549细胞侵袭活性的改变,裸鼠皮下移植瘤模型研究Ad-ODC-AdoMetDCas对体内肺癌生长的抑制作用.实验结果显示,Ad-ODC-AdoMetDCas明显抑制肺癌A-549细胞的增殖,导致细胞凋亡,显著降低肺癌A-549细胞的体外侵袭能力,肺癌A-549细胞感染Ad-ODC-AdoMetDCas后细胞内3种多胺含量都明显降低,Ad-ODC-AdoMetDCas对已形成的裸鼠皮下移植瘤具有明显的抑制作用.实验表明,ODC和AdoMetDC双反义腺病毒具有显著抑制肺癌增殖和侵袭的作用,对于肺癌的防治研究具有一定的前景.     

ODC,AdoMetDC双反义腺病毒对肺癌增殖和侵袭制作用的体外和体内研究

鸟氨酸脱羧酶(ODC)和S-甲硫氨酸脱羧酶(AdoMetDC)是多胺体内合成的2个关键酶.研究腺病毒Ad-ODC-AdoMetDCas介导的ODC和AdoMetDC反义RNA对肺癌多胺合成,细胞增殖以及侵袭的抑制作用.用活细胞计数和流式细胞术分别检测Ad-ODCas和Ad-ODC-AdoMetDCas对肺癌A-549细胞增殖的影响,蛋白质印迹和HPLC方法分别检测腺病毒对肺癌A-549细胞中ODC和AdoMetDC蛋白表达以及胞内多胺含量的抑制作用,TUNEL标记检测法观察Ad-ODC-AdoMetDCas对肺癌细胞凋亡的影响,Matrigel侵袭实验分析腺病毒对肺癌A-549细胞侵袭活性的改变,裸鼠皮下移植瘤模型研究Ad-ODC-AdoMetDCas对体内肺癌生长的抑制作用.实验结果显示,Ad-ODC-AdoMetDCas明显抑制肺癌A-549细胞的增殖,导致细胞凋亡,显著降低肺癌A-549细胞的体外侵袭能力,肺癌A-549细胞感染Ad-ODC-AdoMetDCas后细胞内3种多胺含量都明显降低,Ad-ODC-AdoMetDCas对已形成的裸鼠皮下移植瘤具有明显的抑制作用.实验表明,ODC和AdoMetDC双反义腺病毒具有显著抑制肺癌增殖和侵袭的作用,对于肺癌的防治研究具有一定的前景.     

负载雷公藤甲素的TPGS-b-(PCL-ran-PGA)纳米制剂体外抑制宫颈癌细胞生长的研究

雷公藤甲素（triptolide,TPL）是传统中药雷公藤的主要活性成分,具有抗炎、抗肿瘤活性,但其毒副作用限制了临床上的广泛使用。为了探讨以TPGS-b-(PCL-ran-PGA)为载体制备的TPGS-b-(PCL-ran-PGA)/TPL纳米粒的表征和体外对宫颈癌细胞的抑制作用,采用乳化/溶剂挥发法,优化TPGS-b-(PCL-ran-PGA)与TPL比例,制备TPGS-b-(PCL-ran-PGA)/TPL纳米粒,对纳米粒进行表征,包括粒径大小、ζ电位、包封率、累积释放率,用MTS法体外研究游离型TPL和TPGS-b-(PCL-ran-PGA)/TPL纳米粒对宫颈癌细胞半数抑制浓度（IC50）,用克隆形成实验分析TPGS-b-(PCL-ran-PGA)/TPL纳米粒对宫颈癌细胞HeLa的抑制作用,用流式细胞仪分析纳米粒对HeLa细胞凋亡的影响。结果显示：当TPGS-b-(PCL-ran-PGA)与TPL为50∶1时制备的纳米粒粒径为(95.3±5.2)nm,zeta电位为(-12.2±0.9)mV,其累积释放曲线呈双相分布,TPGS-b-(PCL-ran-PGA)纳米粒对HeLa细胞在24、48和72 h的IC50（2.8、1.8、0.9 μg·L-1）远远低于游离型TPL（P<0.01）,克隆形成实验证明纳米粒能显著抑制肿瘤细胞生长,并能显著诱导HeLa细胞凋亡。研究结果表明,TPGS-b-(PCL-ran-PGA)/TPL纳米粒能抑制宫颈癌细胞HeLa的生长,其作用主要通过TPL和TPGS共同诱导细胞凋亡,可以作为抗宫颈癌等肿瘤的候选药物。     

肉桂醛抗人宫颈癌相关机制的研究

目的探讨不同浓度的肉桂醛对HeLa细胞P21、CDK4蛋白表达的影响及意义。方法不同浓度的经过纯度鉴定的肉桂醛处理体外培养的HeLa细胞,培养24 h后免疫组织化学和Western blotting法检测HeLa细胞P21、CDK4蛋白表达的变化。结果肉桂醛纯度〉96.24%;肉桂醛能显著增高P21和降低CDK4蛋白在HeLa细胞中的表达,各浓度肉桂醛处理组的P21、CDK4蛋白表达与溶剂对照组相比差异均有统计学意义（P〈0.01,P〈0.05）。结论肉桂醛能上调宫颈癌HeLa细胞P21蛋白表达和下调CDK4蛋白表达,可能是促进HeLa细胞凋亡的机制之一。     

合成的哌啶并噻吩类化合物抑制肺癌细胞生长的初步研究

为了发现新的可用于肺癌治疗的小分子药物,从实验室现有的小分子化合物库中,选取13个未见报道的新型哌啶并噻吩类化合物,对其抑制肺癌A549细胞生长的作用进行初步评价。通过体外培养A549细胞,应用WST-1法检测小分子化合物(终浓度为10μmol/L)处理后细胞存活率的变化,发现化合物11(噻吩并[2,3-c]哌啶-3-甲酰胺-2-[(3-甲氧基-萘-2-羰基)-氨基]-6-苄基-,盐酸盐)能显著抑制A549细胞的生长,抑制率可达到(71.34±0.96)%。对小分子化合物结构与活性关系的分析发现苯并结构可能是增强化合物对A549细胞生长的抑制作用的关键结构基团。随后,进一步分析了化合物11(终浓度分别为1、2.5、5、10μmol/L)对A549细胞和正常人胚肺成纤维MRC-5细胞生长的抑制作用。结果表明,随着该化合物浓度增加,对A549细胞生长的抑制率逐渐增大,用GraphPad Prism软件计算出该化合物的IC50为2.407μmol/L;而该化合物对MRC-5细胞生长的抑制率显著低于对A549细胞生长的抑制率,当作用终浓度为10μmol/L时,其对MRC-5细胞生长的抑制率也只有30.41%。这些研究结果初步显示化合物11是一种新的较为理想的治疗肺癌药物先导化合物的候选分子。     

羟基丹参酮ⅡA的合成及体外抗肿瘤作用

对丹参酮ⅡA进行结构修饰,合成了羟基丹参酮ⅡA。采用MTT法考察了羟基丹参酮ⅡA对人宫颈癌细胞株Hela细胞,人肝癌细胞株HepG-2细胞、人胃癌细胞株SGC-7901细胞的增殖抑制作用。结果表明:羟基丹参酮ⅡA对三种肿瘤细胞增殖都有很好的抑制作用,抑制作用呈剂量依赖性。羟基丹参酮ⅡA对SGC-7901细胞抑制作用最强,其IC_(50)为4.18μM;对HeLa细胞的抑制作用次之,其IC_(50)为6.08μM;对HepG-2细胞抑制作用较弱,其IC_(50)为10.20μM。而丹参酮ⅡA对SGC-7901细胞、HeLa细胞和HepG-2细胞的IC_(50)分别是17.15μM、27.28μM和46.34μM。羟基丹参酮ⅡA抑制肿瘤细胞增殖作用明显强于丹参酮ⅡA(P0.05)。     

蒟子的化学成分研究

采用色谱柱层析及半制备高效液相色谱的分离方法,以及质谱和核磁共振波谱的鉴定方法,从蒟子全株中分离、鉴定出了10个化合物,其中4个为新的酰胺类成分,即蒟子酰胺A～D(1～4)。已知化合物包括3个二肽,即短蒟酰胺C～E(5～7),以及3个酰胺,即(E)-N-(3,4,5-三甲氧基肉桂酰基)四氢吡咯(8)、(E)-N-(5-甲氧基-3,4-亚甲二氧基肉桂酰基)四氢吡咯(9)和(Z)-N-(3,4,5-三甲氧基肉桂酰基)四氢吡咯(10)。采用MTS法测试了4个新化合物对5种肿瘤细胞株的体外细胞毒活性,蒟子酰胺A(1)对人白血病HL-60细胞(IC_(50)=10.99μM)、人肝癌SMMC-7721细胞(IC_(50)=17.10μM)、人肺癌A-549细胞株(IC_(50)=7.93μM)、人乳腺癌MCF-7细胞(IC_(50)=16.63μM)和人结肠癌SW480细胞(IC_(50)=9.16μM)的生长有抑制活性。     

骆驼蓬籽蛋白提取物体外抑癌活性的研究

目的:探讨骆驼蓬籽蛋白提取物的体外抑癌活性.方法:采用MTT法检测硫酸铵沉淀的骆驼蓬籽蛋白提取物体外抗肿瘤活性,应用流式细胞术和Annexin V/PI双荧光染色法检测其对细胞凋亡的影响.结果:80%硫酸铵饱和度下的蛋白提取物对宫颈癌HeLa、食道癌Ecal09和肝癌BEL-7404细胞的IC50分别为72.11±3.88μg/mL、257.58±1.16μg/mL和174.07±1.32μg/mL.对HeLa细胞的抑制率与空白对照组相比有显著性差异(P＜0.01),呈现较好的量效关系,且有促进细胞凋亡的作用.结论:骆驼蓬籽蛋白中对HeLa细胞增殖具有较好的抑制活性,可能是通过诱导细胞凋亡来发挥其抗肿瘤作用.     

Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents

Twenty-two quinazoline derivatives have been synthesised and examined for their anti-tumour activity against three tumour cell lines, namely human breast cancer cell line (MCF-7), human cervical cancer cell line (HeLa) and human hepatoma cell line (HepG2). Twelve of the tested compounds have shown promising anti-tumour activity with an IC(50) range of 5.0-9.7 μg/mL. Regarding the spectrum of activity, five compounds exhibited interesting anti-proliferative properties against the three tested cell lines comparable to the reference drug (dasatinib).     

Synthesis, characterization and biological evaluation of some 16E-arylidene androstane derivatives as potential anticancer agents

A series of new 16E-arylidene androstane derivatives were synthesized and characterized. The new compounds were screened for their anticancer activities against the human cancer cell lines SW480, A549, HepG2 and HeLa in vitro using the MTT assay. The results of the in vitro study showed that a number of compounds have shown IC₅₀ values lower than 20 μM against the four cancer cell lines.     

Design,synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents

Twenty-two quinazoline derivatives have been synthesised and examined for their anti-tumour activity against three tumour cell lines, namely human breast cancer cell line (MCF-7), human cervical cancer cell line (HeLa) and human hepatoma cell line (HepG2). Twelve of the tested compounds have shown promising anti-tumour activity with an IC₅₀ range of 5.0–9.7 µg/mL. Regarding the spectrum of activity, five compounds exhibited interesting anti-proliferative properties against the three tested cell lines comparable to the reference drug (dasatinib).     

Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents

A series of resveratrol derivatives possessing curcumin moiety were synthesized and evaluated for their antiproliferative activity against three cancer cell lines including murine melanoma B16-F10, human hepatoma HepG2 and human lung carcinoma A549. Among them, compound C5 displayed the most potent in vitro antiproliferative activity against B16-F10 with IC(50) value of 0.71 μg/mL. Compound C5 also exhibited good tubulin polymerization inhibitory activity with IC(50) value of 1.45 μg/mL. Furthermore, docking simulation was carried out to position C5 into the tubulin-colchicine binding site to determine the probable binding mode.     

The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cells

Sarsasapogenin, a kind of mainly effective components of Anemarrhena asphodeloides Bunge (Liliaceae) has the effects of being anti-diabetes and improving memory. However, there are few reports focusing on its anti-tumor effects. In this study, the sarsasapogenin was extracted from rhizomes of A. asphodeloides Bunge and applied to inhibit HepG2 human hepatoma cells. MTT assay showed that sarsasapogenin induced a distinct dose- and time-dependent diminution of cell viability with IC(50) of 42.4+/-1.0microg/ml for 48h. Furthermore, sarsasapogenin-induced apoptosis of HepG2 cells was verified by Hoechst 33258 staining, electron microscopy, DNA fragmentation and PI staining. Flow cytometry analysis showed that sarsasapogenin-induced cell apoptosis was through arrest of cell cycle in G(2)/M phase. Hence we proposed that sarsasapogenin could be used as an anti-liver cancer drug for future studies.     

Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cells

This study investigated the potential of shikonin as an anticancer agent against liver cancer and an in vitro human hepatoma cancer model system. The HepG2 cell line was the hepatoma cancer model in the present study. The inhibitory effect of shikonin on the growth of HepG2 cells was measured by MTT assay. To explore the underlying mechanism of cell growth inhibition of shikonin, the cell cycle distribution, DNA fragmentation, mitochondrial membrane potential (ΔΨm) disruption, and expression of Bax and Bcl-2 were measured in HepG2 cells. The activity of shikonin in inducing apoptosis was investigated through the detection of Annexin V signal and CD95 expression by flow cytometry and electron microscopy, respectively. Shikonin inhibited the growth of HepG2 cells in a dose-dependent manner. The IC50 value (inhibiting cell growth by 50%) was 4.30 mg/mL. Shikonin inhibited cell growth in a dose-dependent manner and blocked HepG2 cell cycle progression at the S phase. The changes in mitochondrial morphology, dose-dependently decreased in ΔΨm, were observed in different concentrations of the drug treatment group. Western blot analysis showed that cajanol inhibited Bcl-2 expression and induced Bax expression. Furthermore, we show that shikonin increases Annexin V signal and CD95 (Fas/APO) expression, resulting in apoptotic cell death of HepG2 cells. In addition, lump formation of intranuclear chromatin, pyknosis of cell nucleus, deletion of microvillus, vacuolar degeneration of mitochondria, reduction of rough endoplasmic reticulum, and resolution of free ribosome, etc., associated with apoptosis were discovered by electron microscopy in HepG2 cells after 48 h treatment. Shikonin inhibited HepG2 cells, possibly through the pathway of inducing early apoptosis, and was beneficial for restoring the apoptotic sensitivity of HepG2 cells by CD95, and should therefore be considered as a candidate agent for the prevention or treatment of human hepatoma.     

Vitronectin secretion by hepatic and non-hepatic human cancer cells

Summary Thirty-eight human cancer cell lines and subclones derived from 12 different organs were screened for vitronectin secretion in their culture media. By immunoblotting analysis we detected high secretion by three out of five hepatoma cell lines tested but no secretion by the others. In addition, significant secretion was observed in seven non-hepatic cancer cell lines and subclones derived from the cervix, lung, and pancreas. These vitronectin-secreting cells included PLC/PRF/5, HuH-6 #5, HuH-7, HeLa S3, HeLa · P3 #2, #3, #6, #8, A549, and MIAPaCa-2. The results were further confirmed by quantitative analysis using sandwich enzyme-linked immunoassay, and activity analysis of cell attachment promotion on Western blotted filters.     

蓖麻根提取物对HepG2,NCI-H460和SGC-7901细胞增殖及凋亡作用的影响

探讨蓖麻根不同提取物对肝癌HepG2细胞株、肺癌NCI-H460细胞株和胃癌SGC-7901细胞株增殖及其凋亡的影响.采用MTT法检测蓖麻根不同提取物处理48h、72h对HepG2细胞、NCI-H460细胞和SGC-7901细胞增殖的抑制率;Hoechst 33258荧光染料染色法观察HepG2细胞凋亡,流式细胞术检测...     

Two New Norlignans and a New Lignanamide from Peperomia tetraphylla

Two new cyclobutane-type norlignans, methyl rel-(1R,2S,3S)-2-(7-methoxy-1,3-benzodioxol-5-yl)-3-(2,4,5-trimethoxyphenyl)cyclobutanecarboxylate (1), and methyl rel-(1R,2R,3S)-2-(7-methoxy-1,3-benzodioxol-5-yl)-3-(2,4,5-trimethoxyphenyl)cyclobutanecarboxylate (2), and a new lignanamide, 3-hydroxy-N-[2-(4-hydroxyphenyl)ethyl]-α-[4-(2-{N-[2-(4-hydroxyphenyl)ethyl]carbamoyl}ethenyl)-3-methoxyphenoxy]-4-methoxycinnamamide 4,8″-ether (3), along with five known amides, 4-8, were obtained from the whole plant of Peperomia tetraphylla. Their structures were elucidated mainly by the analysis of NMR and MS data. The new compounds 1-3 and the known compound 4 were tested for their cytotoxic activities against the HepG2 (human hepatocarcinoma), A549 (human lung cancer), and HeLa (human cervical cancer) cell lines. Compound 4 showed significant cytotoxicity against HepG2 cell lines with an IC(50) value of 9.4 ± 1.0?μM.